drug · oligonucleotide
nedosiran sodium
Marketedupdated 3mo agoby Novo Nordisk AS🔗 ChEMBL
Approvedcommunity read0 votes
Oligonucleotide drug with a maximum clinical stage of Approval, with an approval for primary hyperoxaluria.
targets
L-lactate dehydrogenase A chain mRNA
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 27, 2028
~1.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (18)
- Oct 12, 2038compositionUS 11286488
- Oct 12, 2038compositionUS 11286488
- Oct 12, 2038compositionUS 11286488
- Oct 12, 2038compositionUS 11661604
- Oct 12, 2038compositionUS 11661604
- Oct 12, 2038compositionUS 11661604
- Oct 29, 2035compositionUS 11053502
- Oct 29, 2035compositionUS 11053502
- Oct 29, 2035compositionUS 11053502
- Oct 9, 2035compositionUS 10351854
- Oct 9, 2035compositionUS 10351854
- Oct 9, 2035compositionUS 10351854
- Oct 9, 2035compositionUS 10738311
- Oct 9, 2035compositionUS 10738311
- Oct 9, 2035compositionUS 10738311
- Oct 9, 2035compositionUS 11359203
- Oct 9, 2035compositionUS 11359203
- Oct 9, 2035compositionUS 11359203
FDA exclusivities (9)
- Sep 29, 2030ODE-443Orphan Drug (7y)4.1y
- Sep 29, 2030ODE-443Orphan Drug (7y)4.1y
- Sep 29, 2030ODE-443Orphan Drug (7y)4.1y
- Sep 29, 2028NCENew Chemical Entity (5y)2.1y
- Sep 29, 2028NCENew Chemical Entity (5y)2.1y
- Sep 29, 2028NCENew Chemical Entity (5y)2.1y
- Mar 27, 2028NPPNew Product (3y)1.6y
- Mar 27, 2028NPPNew Product (3y)1.6y
- Mar 27, 2028NPPNew Product (3y)1.6y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that